Effect of somatotropin of mammalian cell origin in growth hormone deficiency
| Autor: | Barry B. Bercu, Hannen H. Liu, S. Douglas Frasier, Boris Senior, David N. Finegold, Pamela C. Long, Hans J. Zeisel, James F. Marks, Geoffrey P. Redmond, Craig R. Rudlin |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Ratón medicine.medical_treatment Thyroid Gland Dwarfism Growth hormone deficiency law.invention law Internal medicine medicine Humans Insulin Child Growth Disorders Chemotherapy biology business.industry Bone age medicine.disease Recombinant Proteins Endocrinology Glucose Treatment Outcome Child Preschool Growth Hormone Pediatrics Perinatology and Child Health Recombinant DNA biology.protein Female medicine.symptom Antibody business Weight gain |
| Zdroj: | American journal of diseases of children (1960). 146(5) |
| ISSN: | 0002-922X |
| Popis: | • Sixty-nine growth hormone—deficient patients were treated for 1 year with somatotropin (recombinant DNA-derived human growth hormone) produced in mouse cells. The growth velocity of the 50 patients (72%) in whom the effectiveness of this growth hormone could be evaluated increased from a mean (±SD) 3.5±1.1 to 8.7±1.6. cm/y. An enhanced rate of weight gain was also observed. Bone age was not unduly accelerated. One of 66 patients developed antibodies to recombinant growth hormone, which did not affect the response to therapy. No patient developed antibodies to host cell proteins. An increased insulin response to a standard glucose load, without any change in glucose tolerance, was observed after 1 year of treatment. This authentic sequence human growth hormone preparation produced in mammalian cells is both effective and safe in the treatment of children with growth hormone deficiency. ( AJDC . 1992;146:582-587) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|